Company logo

VCYT - Veracyte, Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

VCYT price evolution
VCYT
(in millions $) 30 Oct 2024 30 Jul 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $237 $210.27 $217.33
Short term investments
Net receivables $48.81 $50.3 $46.66 $40.38
Inventory $20.36 $19.26 $18.33 $16.13
Total current assets $356.85 $321.11 $290.42 $285.62
Long term investments
Property, plant & equipment $38.23 $40.41 $32.73 $30.86
Goodwill & intangible assets $864.64 $870.2 $791.58
Total noncurrent assets $913.22 $909.65 $829.28
Total investments
Total assets $1275.02 $1234.33 $1200.07 $1114.91
Current liabilities
Accounts payable $9.67 $12.08 $12.15 $12.94
Deferred revenue $2.19 $2.6 $2.01
Short long term debt $7.18 $5.98 $5.11
Total current liabilities $70.31 $72.34 $58.05 $61.24
Long term debt $0.1 $0.1 $8.06 $7.53
Total noncurrent liabilities $29.46 $23.37 $9.56
Total debt $20.74 $14.04 $12.63
Total liabilities $98.98 $101.8 $81.42 $70.8
Shareholders' equity
Retained earnings -$449.1 -$464.25 -$469.99 -$468.12
Other shareholder equity -$21.28 -$30.61 -$28.91 -$24.02
Total shareholder equity $1132.52 $1118.65 $1044.1
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $217.33 $155 $173.95 $349.97
Short term investments $24.61
Net receivables $40.38 $44.02 $41.46 $18.46
Inventory $16.13 $14.29 $11.22 $4.66
Total current assets $285.62 $248.64 $243.1 $375.68
Long term investments
Property, plant & equipment $30.86 $30.86 $31.14 $16.83
Goodwill & intangible assets $791.58 $870.76 $910.63 $62.65
Total noncurrent assets $829.28 $907.79 $944.72 $81.48
Total investments $24.61
Total assets $1114.91 $1156.42 $1187.83 $457.16
Current liabilities
Accounts payable $12.94 $11.91 $12.36 $3.12
Deferred revenue $2.01 $2.61 $4.99 $1.2
Short long term debt $5.11 $4.07 $4.76 $1.59
Total current liabilities $61.24 $62.61 $64.15 $16.78
Long term debt $7.53 $0.4 $14.1 $10.73
Total noncurrent liabilities $9.56 $18.61 $27.16 $19.15
Total debt $12.63 $14.72 $18.85 $12.32
Total liabilities $70.8 $81.22 $91.31 $35.93
Shareholders' equity
Retained earnings -$468.12 -$393.72 -$357.16 -$281.59
Other shareholder equity -$24.02 -$31.35 -$15.08
Total shareholder equity $1044.1 $1075.2 $1096.51 $421.23
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $114.43 $96.84 $98.2
Cost of revenue $36.52 $31.46 $29.38
Gross Profit $77.91 $65.38 $68.82
Operating activities
Research & development $16.46 $15.96 $18.67
Selling, general & administrative $55.96 $49.99 $49.05
Total operating expenses $73.31 $70.04 $104.33
Operating income $4.61 -$4.66 -$35.51
Income from continuing operations
EBIT $7.36 -$1.91 -$30.47
Income tax expense $1.63 -$0.04 -$2.18
Interest expense
Net income
Net income $5.73 -$1.86 -$28.29
Income (for common shares) $5.73 -$1.86 -$28.29
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $361.05 $296.54 $219.51 $117.48
Cost of revenue $112.9 $101.58 $74.4 $41.45
Gross Profit $248.15 $194.95 $145.11 $76.03
Operating activities
Research & development $57.3 $40.6 $29.84 $17.2
Selling, general & administrative $187.72 $174.08 $181.19 $89.12
Total operating expenses $333.94 $236.03 $227.02 $111.42
Operating income -$85.8 -$41.08 -$81.9 -$35.39
Income from continuing operations
EBIT -$76.61 -$36.43 -$81.65 -$34.68
Income tax expense -$2.21 $0.13 -$6.09
Interest expense $0.23
Net income
Net income -$74.4 -$36.56 -$75.56 -$34.91
Income (for common shares) -$74.4 -$36.56 -$75.56 -$34.91
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income $5.73 -$1.86 -$28.29
Operating activities
Depreciation $6.89 $6.73 $7.36
Business acquisitions & disposals $5.01
Stock-based compensation $9.85 $8.02 $7.51
Total cash flows from operations $29.57 -$8.97 $15.55
Investing activities
Capital expenditures -$2.77 -$2.13 -$2.5
Investments
Total cash flows from investing -$2.13 -$2.77 $2.88 -$2.5
Financing activities
Dividends paid
Sale and purchase of stock $1.29 $2.97 $1.77
Net borrowings
Total cash flows from financing $9.41 -$0.01 -$0.86 $0.65
Effect of exchange rate -$0.02 -$0.06 -$0.11 $0.3
Change in cash and equivalents $57.83 $26.79 -$6.95 $13.7
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$74.4 -$36.56 -$75.56 -$34.91
Operating activities
Depreciation $31.35 $29.25 $21.23 $8.91
Business acquisitions & disposals -$736.83
Stock-based compensation $33.14 $26.73 $22.52 $12.99
Total cash flows from operations $44.22 $7.54 -$31.62 -$9.71
Investing activities
Capital expenditures -$9.96 -$8.55 -$5.38 -$2.84
Investments $25.07 -$20.84 $3 -$1
Total cash flows from investing $15.11 -$29.39 -$739.21 -$3.84
Financing activities
Dividends paid
Sale and purchase of stock $9.58 $7.94 $605.35 $207.54
Net borrowings -$1.28 -$0.1
Total cash flows from financing $2.84 $3.49 $596.32 $203.59
Effect of exchange rate $0.16 -$0.59 -$1.51
Change in cash and equivalents $62.17 -$18.36 -$174.51 $190.05
Fundamentals
Market cap $3.17B
Enterprise value N/A
Shares outstanding 77.49M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 0.07
Net debt/EBITDA N/A
Current ratio 5.08
Quick ratio 4.79